Total Funding
6
Total FundingGrant raised
Growth Score
pts
Heat Score
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
399727
AveXis is a Biotech company is focused on developing gene therapy for patients with rare and life-threatening neurological genetic diseases.
Lucie Bruijn: Senior Director, Translational Medicine, EMEAPast Role: The ALS Association, Chief Scientist- Phillip Donenberg: Senior Vice President, Chief Financial OfficerPast Role: BioSante Pharmaceuticals, CFO
About the Company
AveXis , doing business as Novartis Gene Therapies, Inc., is a biotechnology company that specializes in the development and commercialization of gene therapies for patients and families affected by rare and life-threatening neurological genetic diseases.
AveXis was acquired by Novartis on May 14, 2018. In 2020, the company was renamed Novartis
Gene Therapies.
